References
1. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35(3):265-271.
2. Zoega H, Kieler H, Norgaard M, et al. Use of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and Sweden. PLoS One. 2015;10(12):e0144474.
3. Charlton RA, Jordan S, Pierini A, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG.2015;122(7):1010-1020.
4. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci.2003;4(12):1002-1012.
5. Sujan AC, Oberg AS, Quinn PD, D’Onofrio BM. Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research. J Child Psychol Psychiatry. 2019;60(4):356-376.
6. Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. Neurosci Biobehav Rev.2018;86:1-11.
7. Hjorth S, Bromley R, Ystrom E, Lupattelli A, Spigset O, Nordeng H. Use and validity of child neurodevelopment outcome measures in studies on prenatal exposure to psychotropic and analgesic medications - A systematic review. PLoS One. 2019;14(7):e0219778.
8. Lupattelli A, Wood M, Ystrom E, Skurtveit S, Handal M, Nordeng H. Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Aged Children. J Am Acad Child Adolesc Psychiatry. 2018;57(3):200-208.
9. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision.Lancet Psychiatry. 2018;5(2):175-186.
10. Magnus P, Birke C, Vejrup K, et al. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol.2016;45(2):382-388.
11. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol.2006;35(5):1146-1150.
12. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-439.
13. Norwegian Institute of Public Health. Norwegian Prescription Database (NorPD). https://www.fhi.no/en/hn/health-registries/norpd/. Published 2019. Accessed 19 March, 2019.
14. Bakken IJ, Suren P, Haberg SE, Cappelen I, Stoltenberg C. [The Norwegian patient register–an important source for research].Tidsskr Nor Laegeforen. 2014;134(1):12-13.
15. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology.2008;19(6):766-779.
16. Wood ME, Lapane KL, van Gelder M, Rai D, Nordeng HME. Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. Pharmacoepidemiol Drug Saf. 2018;27(2):140-147.
17. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry. 2003;57(2):113-118.
18. Tambs K, Moum T. How well can a few questionnaire items indicate anxiety and depression? Acta Psychiatr Scand. 1993;87(5):364-367.
19. Norwegian Institute of Public Health. The Nowegian Mother and Child Cohort Study. Questionnaires. Norwegian Institute of Public Health. https://fhi.no/en/studies/moba/for-forskere-artikler/questionnaires-from-moba/. Accessed August 5, 2019.
20. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 2012. http://www.whocc.no/atc_ddd_index/. Accessed 17 March, 2017.
21. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. J Clin Epidemiol.2013;66(9):964-972.
22. Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng H. Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers.JAMA Netw Open. 2019;2(4):e191435.
23. Ørstavik R, Gustavson K, Rohrer-Baumgartner N, et al. ADHD i Norge. Folkehelseinstituttet 2016.
24. ADHD and hyperkinetic disorder. In: Rutter’s Child and Adolescent Psychiatry. 738-756.
25. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol.1998;26(4):257-268.
26. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology. 2011;22(5):745.
27. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol.2013;122(5):957-965.
28. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch Gen Psychiatry. 1993;50(11):863-870.
29. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.Stat Med. 2015;34(28):3661-3679.
30. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology.2000;11(5):550-560.
31. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
32. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
33. Moodie EE, Delaney JA, Lefebvre G, Platt RW. Missing confounding data in marginal structural models: a comparison of inverse probability weighting and multiple imputation. The international journal of biostatistics. 2008;4(1):Article 13.
34. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol. 2009;23(6):597-608.
35. Biele G, Gustavson K, Czajkowski NO, et al. Bias from self selection and loss to follow-up in prospective cohort studies. Eur J Epidemiol. 2019;34(10):927-938.
36. Malm H, Brown AS, Gissler M, et al. Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. J Am Acad Child Adolesc Psychiatry. 2016;55(5):359-366.
37. Grzeskowiak LE, Morrison JL, Henriksen TB, et al. Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG.2016;123(12):1919-1928.
38. Jiang HY, Peng CT, Zhang X, Ruan B. Antidepressant use during pregnancy and the risk of attention-deficit/hyperactivity disorder in the children: a meta-analysis of cohort studies. BJOG.2018;125(9):1077-1084.
39. Hernán MA. The Hazards of Hazard Ratios. Epidemiology.2010;21(1):13-15.
40. Boukhris T, Sheehy O, Berard A. Antidepressant Use in Pregnancy and the Risk of Attention Deficit with or without Hyperactivity Disorder in Children. Paediatr Perinat Epidemiol. 2017.
41. Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017;357:j2350.
42. Sujan AC, Rickert ME, Oberg AS, et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA.2017;317(15):1553-1562.
43. Laugesen K, Olsen MS, Telen Andersen AB, Froslev T, Sorensen HT. In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ open. 2013;3(9):e003507.
44. El Marroun H, White T, Verhulst FC, Tiemeier H. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(10):973-992.
45. Maoz H, Goldstein T, Goldstein BI, et al. The effects of parental mood on reports of their children’s psychopathology. J Am Acad Child Adolesc Psychiatry. 2014;53(10):1111-1122.e1115.
46. Galéra C, Côté SM, Bouvard MP, et al. Early Risk Factors for Hyperactivity-Impulsivity and Inattention Trajectories From Age 17 Months to 8 Years. Arch Gen Psychiatry. 2011;68(12):1267-1275.
47. Schrantee A, Lucassen PJ, Booij J, Reneman L. Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity. Eur Neuropsychopharmacol. 2018;28(10):1173-1179.
48. Samuele Cortese, M.D., Ph.D. ,, Clare Kelly, Ph.D. ,, Camille Chabernaud, Ph.D. ,, et al. Toward Systems Neuroscience of ADHD: A Meta-Analysis of 55 fMRI Studies. Am J Psychiatry.2012;169(10):1038-1055.
49. Eilertsen EM, Gjerde LC, Kendler KS, et al. Development of ADHD symptoms in preschool children: Genetic and environmental contributions. 2019;31(4):1299-1305.